Skip to content

Ananda Developments - Patent Applications Filed

Announcement provided by

Ananda Developments Plc · ANA

17/05/2023 07:00

Ananda Developments - Patent Applications Filed
RNS Number : 6399Z
Ananda Developments PLC
17 May 2023

17 May 2023


("Ananda" or the "Company")

Patent Applications Filed

Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, is pleased to announce that its wholly owned subsidiary MRX Medical Limited, has filed four patent applications with the UK government's Intellectual Property Office.

The applications cover three cannabinoid formulations known as MRX1, MRX2 and its most recently invented formulation MRX3. These formulations are being developed as cannabidiol-based medicines for the treatment of a number of complex inflammatory indications which are unmet by existing treatments. The fourth application covers a proprietary method for formulating these products.

The MRX1 formulation is to be used as the Active Pharmaceutical Ingredient (API) in two upcoming Phase II Randomised Control Trials (RCTs) to be conducted by the University of Edinburgh. One trial is investigating the effect of cannabidiol on chemotherapy induced peripheral neuropathy (CIPN) and the other is investigating the effect of cannabidiol on endometriosis.

Ananda's CEO, Melissa Sturgess, commented: "The filing of these patent applications is an important step as we build Ananda. The patent applications will protect the Company's intellectual property and help to build value for shareholders."


The Directors of the Company accept responsibility for the contents of this announcement.



+44 (0)7463 686 497

Chief Executive Officer

Melissa Sturgess

Executive Director

Jeremy Sturgess-Smith


+44 (0)20 3470 0470

Corporate Finance

Richard Morrison

Harry Davies-Ball


Corporate Broking

Abigail Wayne

Rob Rees


About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For more information, please visit:


Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

ANA announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal